Tamoxifen

Generic Name: Tamoxifen

Brand Names: Soltamox

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₉NO

CAS Number: 10540-29-1

Unique Ingredient Identifier: 094ZI81Y45

Background: Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.

Tamoxifen was granted FDA approval on 30 December 1977.

Indication: Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions: Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer

Associated Therapies: Ovulation induction therapy

Clinical Trials

Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen

First Posted Date: 2005-09-20

Last Posted Date: 2015-04-29

Lead Sponsor: International Breast Cancer Research Foundation

Target Recruit Count: 740

Registration Number: NCT00201851

Locations: 🇲🇦
National Institute of Oncology, Rabat, Morocco
🇵🇭
Vicente Soto Memorial Medical Center, Cebu, Philippines
🇵🇭
East Avenue Medical Center, Manila, Philippines

and more 6 locations

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Phase 2

Completed

Conditions: Ovarian Cancer
Cancer of the Fallopian Tube
Peritoneal Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2010-07-20

Lead Sponsor: AGO Study Group

Registration Number: NCT00189358

Locations: 🇩🇪
Dept. of Gynecology, Evangelisches Krankenhaus, Duesseldorf, Germany

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Phase 2

Terminated

Conditions: Breast Carcinoma

Interventions: Drug: Fulvestrant
Drug: Tamoxifen

First Posted Date: 2005-09-16

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 4

Registration Number: NCT00183963

Locations: 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States

A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

Phase 3

Completed

Conditions: Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

Interventions: Drug: Letrozole
Drug: Tamoxifen

First Posted Date: 2005-09-15

Last Posted Date: 2017-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 263

Registration Number: NCT00171704

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Not Applicable

Completed

Conditions: Hodgkin's Disease
Breast Cancer

Interventions: Drug: Tamoxifen

First Posted Date: 2005-09-14

Last Posted Date: 2014-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00165308

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: bevacizumab
Drug: paclitaxel
Biological: filgrastim
Biological: pegfilgrastim
Radiation: radiation therapy
Drug: tamoxifen citrate
Drug: aromatase inhibition therapy

First Posted Date: 2005-07-13

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 226

Registration Number: NCT00119262

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2

Completed

Conditions: Male Breast Carcinoma
Estrogen Receptor Positive
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Progesterone Receptor Positive
Stage IV Breast Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lapatinib Ditosylate
Drug: Tamoxifen Citrate

First Posted Date: 2005-07-11

Last Posted Date: 2017-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00118157

Locations: 🇺🇸
Harper University Hospital - DMC, Detroit, Michigan, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

Phase 2

Completed

Conditions: Glioma

Interventions: Drug: Tamoxifen citrate
Drug: Bortezomib

First Posted Date: 2005-04-13

Last Posted Date: 2015-11-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT00108069

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate

First Posted Date: 2004-06-09

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT00003992

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 42 locations

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Doxorubicin
Drug: Tamoxifen

First Posted Date: 2004-05-21

Last Posted Date: 2010-02-03

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 2411

Registration Number: NCT00002707

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States

and more 142 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy